Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
CAPR
vs
S&P 500
CAPR
S&P 500
Over the past 12 months, CAPR has underperformed S&P 500, delivering a return of +16% compared to S&P 500's +16% growth.
Stocks Performance
CAPR vs S&P 500
Performance Gap
CAPR vs S&P 500
Performance By Year
CAPR vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Capricor Therapeutics Inc
Glance View
Capricor Therapeutics is a biotechnology company that develops cell-based medicines for serious diseases, with a main focus on heart and muscle disorders. Its lead program is deramiocel, an allogeneic cardiosphere-derived cell therapy being studied for Duchenne muscular dystrophy, a genetic disease that weakens muscles over time. The company also works on exosome-based therapies, which use tiny particles released by cells as a way to deliver treatment signals. The company does not sell a broad range of drugs. It earns money mainly through research and development funding, collaboration payments, and, if its programs succeed, potential future product sales or licensing deals. Its main customers are not typical consumers; they are regulators, research partners, doctors, hospitals, and eventually patients and payers if a therapy reaches the market. What makes Capricor different is that it sits very early in the drug-development chain and focuses on hard-to-treat rare diseases where standard medicines often do not help enough. Instead of making mass-market pills, it is building specialized biologic treatments that must be tested, approved, and then delivered through clinical and medical channels.